Tianmu
Tianmu (天目药业) is a Chinese pharmaceutical brand name; the supplied evidence does not confirm its current operations.
Last updated October 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Tianmu (天目药业) is presented here as a Chinese pharmaceutical brand. The only supplied evidence is a domain-parking page reached at the brand's website address, which states that the domain may be for sale and does not contain any product, corporate, or operational information about the brand. Because the evidence does not describe Tianmu's business, ownership, products, or current status, this dossier is intentionally limited and should be treated as unverified. No founding date, headquarters, executives, products, or financial details can be confirmed from the available material. The entry is flagged for review so that a future editor can replace it with a properly sourced profile once reliable brand evidence is available.
History
No verifiable history of the Tianmu brand can be written from the supplied evidence. The only source is a parked-domain page at the brand's website address, which offers the domain for sale and contains no corporate history, founding information, or operational record. As a result, no dated milestones or historical narrative are included here. A future revision should rely on official filings, company announcements, or reputable business databases before adding historical content.
Products and positioning
Controversies
2020
CSRC opens investigation into Tianmu Pharmaceutical
Tianmu Pharmaceutical said it received an investigation notice from the China Securities Regulatory Commission on April 21, 2020. The regulator decided to open an investigation into the company over suspected violations involving information disclosure. The article also reports allegations concerning undisclosed related-party guarantees and loans. The notice and the reported allegations are described as stated in the source; no further details on the investigation's scope or outcome are provided.
Recent events
CSRC opens investigation into Tianmu Pharmaceutical[2]
Reported:
Tianmu Pharmaceutical said it received a China Securities Regulatory Commission investigation notice on April 21. The regulator decided to investigate the company over suspected violations involving information disclosure. The article also reports allegations concerning undisclosed related-party guarantees and loans.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/tianmu · Editorial policy · How profiles are compiled